792 related articles for article (PubMed ID: 18781676)
1. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
Jenner P
Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676
[TBL] [Abstract][Full Text] [Related]
2. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease.
Stocchi F
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S68-71. PubMed ID: 20083012
[TBL] [Abstract][Full Text] [Related]
4. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Olanow CW; Obeso JA; Stocchi F
Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates.
Jenner P
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S90-9; discussion S99-104. PubMed ID: 10762136
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
Fox SH; Chuang R; Brotchie JM
Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
[TBL] [Abstract][Full Text] [Related]
8. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Damier P; Tremblay L; Féger J; Hirsch EC
Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
[TBL] [Abstract][Full Text] [Related]
9. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
10. Levodopa in the treatment of Parkinson's disease: current controversies.
Olanow CW; Agid Y; Mizuno Y; Albanese A; Bonuccelli U; Damier P; De Yebenes J; Gershanik O; Guttman M; Grandas F; Hallett M; Hornykiewicz O; Jenner P; Katzenschlager R; Langston WJ; LeWitt P; Melamed E; Mena MA; Michel PP; Mytilineou C; Obeso JA; Poewe W; Quinn N; Raisman-Vozari R; Rajput AH; Rascol O; Sampaio C; Stocchi F
Mov Disord; 2004 Sep; 19(9):997-1005. PubMed ID: 15372588
[TBL] [Abstract][Full Text] [Related]
11. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
Olanow CW
Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
[TBL] [Abstract][Full Text] [Related]
12. [Current preclinical findings on substances against Parkinson's disease].
Gerlach M; Riederer P
Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677
[TBL] [Abstract][Full Text] [Related]
13. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets.
Stockwell KA; Virley DJ; Perren M; Iravani MM; Jackson MJ; Rose S; Jenner P
Exp Neurol; 2008 May; 211(1):172-9. PubMed ID: 18321484
[TBL] [Abstract][Full Text] [Related]
14. Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.
Papathanou M; van der Laan R; Jenner P; Rose S; McCreary AC
Mov Disord; 2013 Jul; 28(8):1072-9. PubMed ID: 23125107
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of L-DOPA-induced dyskinesia.
Jenner P
Nat Rev Neurosci; 2008 Sep; 9(9):665-77. PubMed ID: 18714325
[TBL] [Abstract][Full Text] [Related]
16. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.
Olanow CW; Obeso JA
Neurology; 2000; 55(11 Suppl 4):S72-7; discussion S78-81. PubMed ID: 11147513
[TBL] [Abstract][Full Text] [Related]
17. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
Smith LA; Jackson MJ; Al-Barghouthy G; Rose S; Kuoppamaki M; Olanow W; Jenner P
Mov Disord; 2005 Mar; 20(3):306-14. PubMed ID: 15490461
[TBL] [Abstract][Full Text] [Related]
18. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Zhang H; Ma L; Wang F; Chen J; Zhen X
Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
[TBL] [Abstract][Full Text] [Related]
19. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
Jenner P
Neurology; 2004 Jan; 62(1 Suppl 1):S47-55. PubMed ID: 14718680
[TBL] [Abstract][Full Text] [Related]
20. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
Tayarani-Binazir K; Jackson MJ; Rose S; McCreary AC; Jenner P
Exp Neurol; 2010 Dec; 226(2):320-7. PubMed ID: 20843474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]